Constitutive activation of the PI3K/Akt/mTOR pathway occurs in 50%–80% of AML patients and is linked to reduced OS (Bertacchini et al., 2014; Darici et al., 2020). This evidence concerns the gene MTOR and acute myeloid leukemia.